Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 9/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8722824 | 0.81 | TYMS (0.37) | TYMS | |
| SCHEMBL6885646 | 0.81 | POLB (0.41) | TYMSMEN1KMT2AMAPTTDP1 | |
| SCHEMBL6885650 | 0.81 | POLB (0.41) | TYMSMEN1KMT2AMAPTTDP1 | |
| SCHEMBL8723947 | 0.80 | TYMS (0.35) | TYMS | |
| SCHEMBL8721880 | 0.79 | ALOX5 (0.36) | TYMSMAPTTDP1DHFR | |
| SCHEMBL9228554 | 0.79 | ALOX5 (0.36) | TYMSMAPTTDP1DHFR | |
| SCHEMBL9782470 | 0.79 | ALOX5 (0.36) | TYMSMAPTTDP1DHFR | |
| SCHEMBL6885928 | 0.78 | TYMS (0.37) | TYMSMAPTTDP1DHFR | |
| SCHEMBL6885924 | 0.78 | TYMS (0.37) | TYMSMAPTTDP1DHFR | |
| SCHEMBL9782611 | 0.76 | ITGA4 (0.43) | ALDH1A1MEN1KMT2AMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259878-A1 | Fluoromethotrexates and uses therefor | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259878-A1 | Fluoromethotrexates and uses therefor | MTX1, DHFR, SLC46A1 | TYMS 22/4885HCRTR1 3157/4885ALDH1A1 1479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.